News & Updates

Increasing the frequency of CT scan and carcinoembryonic antigen (CEA) testing does not appear to produce a significant reduction in 10-year overall mortality or colorectal cancer–specific mortality for patients with stage II or III colorectal cancer (CRC), according to a study.

Professor Jean-Jacques Kiladjian, Professor of Clinical Pharmacology, Consultant Haematologist, and head of the Clinical Investigation Centre of Hôpital Saint-Louis & Université Paris Cité in Paris, France, discusses the drawbacks of conventional therapy for PV, and how ropeginterferon alfa-2b may support a shift in treatment.

MIMS Oncology explores the current landscape of polycythaemia vera management in Singapore and the role of the newly launched ropeginterferon alfa-2b in improving patient outcomes. During an interview, Dr Dawn Mya, a leading haematologist practicing at Parkway Cancer Centre, Singapore, provides expert insights into the therapeutic potential of this novel treatment.

Evidence from a large population-based study shows no consistent association between an increased risk of cancer and exposure to antihypertensive drugs.

Women with early-stage breast cancer (BC) entering randomized controlled trials (RCTs) after the 2000s have reduced rates of distant recurrence vs the 1990s, a patient-level pooled analysis by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) has shown. 

The novel, small-molecule, orally administered third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) olverembatinib is well-tolerated and shows promising antitumour activity in patients with heavily pretreated chronic-phase chronic myeloid leukaemia (CML), according to the results of a phase 1B study.